In our multicentric study, a relevant proportion (56%) of ARVC patients was anti-DSG2-ab-positive, with significantly higher titer than controls, confirming previous findings obtained in smaller cohorts [11]. Here, DSG2 is linked to arrhythmogenic right ventricular cardiomyopathy.